Buy Rating on Vericel: Expanding MACI's Market Potential and Sustaining Top-Line Growth
Truist Lifts Price Target on Vericel to $57 From $56, Maintains Buy Rating
Vericel Analyst Ratings
Vericel Analyst Ratings
Vericel's Strong Q1 Performance and Growth Potential Affirm Buy Rating
Critical Insights From Vericel Analyst Ratings: What You Need To Know
Vericel Analyst Ratings
Vericel Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Inotiv (NOTV) and Vericel (VCEL)
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), OmniAb (OABI) and Vericel (VCEL)
Analysts Conflicted on These Healthcare Names: Vericel (VCEL), Tenet Healthcare (THC) and Veeva Systems (VEEV)
Vericel Analyst Ratings
Buy Rating Affirmed for Vericel on Strong Financials and Growth Prospects
BTIG Keeps Their Buy Rating on Vericel (VCEL)
BTIG Remains a Buy on Vericel (VCEL)
Vericel Upgraded at Truist on Growth Acceleration Potential
Vericel Analyst Ratings
HC Wainwright & Co. Maintains Buy on Vericel, Raises Price Target to $46
Vericel Analyst Ratings
Leerink Partners Remains a Buy on Vericel (VCEL)